MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
Zai Lab Limited (NASDAQ: ZLAB)*
Organization & Developments: Zai Lab
Parents
Zai Lab Limited (NASDAQ: ZLAB)*
Children
*Chinese authorities approved the compound for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy
*Global impact: A proven China commercialization bridge for global biotechs, accelerating patient access in the world’s second-largest pharma market.
*Multiple first-in-class therapies launched in China via partnerships, including ovarian cancer drug niraparib.
*The company has in-licensed rights to ZEJULA from GlaxoSmithKline (GSK) for Mainland China, Hong Kong and Macau.
*Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, infectious, and autoimmune diseases in China and internationally.
2020: Zai Lab_FiercePharma
2022: Zai Lab: Shares Are Cheap, But Not Without Reason_seekingalpha.com
2022: Zai Labs: Biopharma's Alibaba, But Better_ seekingalpha.com
2023: Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade)_ seekingalpha.com
2024: Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
2024: Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
2024: Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025
2024:P Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
2025: Zai Lab Limited: Banking On Chinese Pharma Growth
2025: Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
2025: Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Jumps
Finance & Acquisitions: Zai Lab
Key People: Zai Lab